LabMed
Prekallikrein Deficiency – Congenital
-
At a Glance
-
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
-
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
-
What Lab Results Are Absolutely Confirmatory?
-
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
At a Glance
Prekallikrein deficiency is a rare disorder seen in all ethnic groups. It is autosomal recessive in inheritance. It is associated with a mildly prolonged partial thromboplastin time (PTT) that will correct when incubated on the bench with all reagents for 1 hour. Its deficiency is not associated with bleeding.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Test results consistent with a diagnosis of prekallikrein deficiency include PTT 35-45 sec and a low value for a plasma prekallikrein assay (coagulant or chromogenic).(
Table 1
Test Results Indicative of the Disorder
APTT | Plasma Prekallikrein Assay |
---|---|
35-45 sec | <10% |
Are There Any Factors That Might Affect the Lab Results? In particular, does your patient take any medications - OTC drugs or Herbals - that might affect the lab results?
Anticoagulants that interfere with clot-based assay, such as unfractionated heparin, enoxaparin, argatroban, bivalirudin, hirudin, and dabigatran, will interfere with laboratory results.
What Lab Results Are Absolutely Confirmatory?
Low prekallikrein assay with no evidence for a defect in other intrinsic coagulation factors and no lupus anticoagulant is absolutely confirmatory.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Low prekallikrein assay without evidence for an inhibitor to plasma prekallikrein should be requested.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
ONA Articles
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |